TAGOVAMERAN
UNII BV8R57Y3YG

Substance Identification & Data

This profile provides standardized clinical and technical data for Tagovameran, uniquely identified by the FDA Unique Ingredient Identifier (UNII) BV8R57Y3YG.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2923496-70-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

BV8R57Y3YG

CAS Registry Number

2923496-70-0

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TAGOVAMERAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C215773

National Cancer Institute reference terminology for clinical and research data.

INN ID

13639

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

nucleicAcid

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tagovameran. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

TAGOVAMERAN

Common Names & Synonyms

RNA (RECOMBINANT 5'-(M7G-(5'->5')-PPP-AM)-CAPPED VENEZUELAN EQUINE ENCEPHALITIS VIRUS RNA-DEPENDENT RNA POLYMERASE (551-ARGININE,739-LEUCINE) CODON-OPTIMIZED TRANSGENE PLUS SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN (682-GLYCINE,683-SERINE,685-SERINE,986-PROLINE,987-PROLINE) BA.4 AND BA.5 VARIANT PRECURSOR-SPECIFYING PLUS 5'- AND 3'-UNTRANSLATED FLANKING REGION-CONTAINING POLY(A)-TAILED MESSENGER MRNA-2317), INNER SALT

SELF-AMPLIFYING MESSENGER RNA (MRNA), 5'-CAPPED, ENCODING CODONOPTIMISED VENEZUELAN EQUINE ENCEPHALITIS VIRUS (VEEV) RNA-DEPENDENT RNA POLYMERASE COMPLEX (VEEV PROTEINS NSP1, NSP2, NSP3 AND NSP4) AND A FULL-LENGTH CODON-OPTIMISED PRE-FUSION STABILISED CONFORMATION VARIANT (K981P AND V982P) OF THE SARS-COV-2 (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2) SPIKE (S) GLYCOPROTEIN BA.4/BA.5 VARIANT (DERIVED FROM GENBANK ID: UVX18152) CONTAINING FURIN CLEAVAGEINACTIVATING MUTATIONS (R677G, R678S AND R680S), FLANKED BY 5' AND 3' UNTRANSLATED REGIONS AND A 3' POLYADENYLATION (POLY(A) TAIL; GENERATION OF CAPPED S GLYCOPROTEIN MRNA IS UNDER CONTROL OF A VEEV SUBGENOMIC PROMOTER

TAGOVAMERAN [INN]

External Clinical & Regulatory Resources

Previous UNIIBV89R7E6Y3

Next UNIIBV8RO40S9Y